Halozyme Therapeutics Inc
HALOHealthcare|Biotechnology|USA
$76.19
-2.42 (-3.08%)
DCF (FCF)
$39.38
Earnings Power
$18.42
Clinical Trials (48)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05625399 A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | Melanoma | P3 | Active | 579 | RCT, Open-label | Nivolumab + Relatlimab, rHuPH20 |
| NCT06689085 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism | Hypogonadism, Male | P3 | Recruiting | 100 | Open-label | — |
| NCT02921022 Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | N/A | Active | 110 | Open-label | Gemcitabine, Nab-paclitaxel, PEGPH20 |
| NCT00369187 Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase | Rheumatoid Arthritis | P4 | Completed | 15 | Open-label | large protein molecule |
| NCT01526733 Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase | Type 1 Diabetes Mellitus | P4 | Completed | 25 | RCT, Double-blind | Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro |
| NCT00311519 A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects | Healthy | P4 | Completed | 50 | RCT, Double-blind | Hylenex |
| NCT01848990 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) | Type 1 Diabetes Mellitus | P4 | Completed | 456 | RCT, Open-label | Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine |
| NCT03662334 A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) | Type 1 Diabetes Mellitus | P4 | Completed | 14 | RCT, Double-blind | Rapid Acting insulin with pre-treatment of rHuPH20 |
| NCT01116102 Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) | Dehydration | P4 | Terminated | 20 | RCT, Open-label | Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution |
| NCT00477152 Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children | Dehydration | P4 | Completed | 52 | Open-label | hyaluronidase (human recombinant)/rehydration fluid |
| NCT00656370 Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) | Healthy | P4 | Completed | 15 | RCT, Double-blind | recombinant human hyaluronidase |
| NCT00807885 Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase | Dehydration | P4 | Completed | 100 | RCT, Open-label | hylenex-facilitated subcutaneous Lactated Ringer's infusion |
| NCT00773175 Subcutaneous Rehydration Compared to Intravenous Rehydration | Dehydration | P4 | Completed | 148 | RCT, Open-label | recombinant human hyaluronidase |
| NCT01120431 Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED) | Dehydration | P4 | Withdrawn | — | RCT, Open-label | Isotonic hydration fluid and recombinant human hyaluronidase |
| NCT02715804 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Carcinoma | P3 | Terminated | 492 | RCT, Double-blind | Placebo, nab-Paclitaxel, Gemcitabine |
| NCT00593281 INFUSE Morphine Study | Pain | P3 | Completed | 13 | RCT, Double-blind | Hylenex |
| NCT02753595 Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) | Metastatic Breast Cancer | P1P2 | Terminated | 25 | RCT, Open-label | Eribulin mesylate, Eribulin mesylate, Eribulin mesylate |
| NCT03979066 Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P2 | Terminated | 1 | RCT, Open-label | Atezolizumab, PEGPH20 |
| NCT03281369 A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | P1P2 | Completed | 214 | RCT, Open-label | 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Atezolizumab, Cobimetinib, Cisplatin, Tiragolumab, 5-Fluorouracil (5-FU) |
| NCT01839487 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | Metastatic Pancreatic Cancer | P2 | Completed | 279 | RCT, Open-label | PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin |
| NCT01194245 Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P2 | Completed | 135 | RCT, Double-blind | Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine |
| NCT03634332 Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | P2 | Unknown | 35 | Open-label | PEGPH20, Pembrolizumab |
| NCT00883558 Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P2 | Completed | 48 | RCT, Open-label | Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine |
| NCT01426763 A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase | Hereditary Angioedema | P2 | Completed | 12 | Open-label | CINRYZE with rHuPH20 |
| NCT01959139 S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | P1P2 | Completed | 126 | RCT, Open-label | PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil |
| NCT00774800 Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P2 | Completed | 22 | Single-blind | Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20) |
| NCT00318643 Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | Bladder Cancer | P1P2 | Completed | 27 | Open-label | Mitomycin C, Chemophase |
| NCT04134468 MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P2 | Withdrawn | — | Open-label | Pegvorhyaluronidase alfa, Abraxane, Gemcitabine |
| NCT01453153 Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | Stage IV Pancreatic Cancer | P1P2 | Completed | 28 | RCT, Double-blind | Gemcitabine, PEGPH20, Placebo |
| NCT01194258 Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type II | P2 | Completed | 132 | RCT, Double-blind | Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine |
| NCT00928447 Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis | Dermatitis, Allergic Contact | P2 | Completed | 22 | RCT, Double-blind | rHuPH20, Placebo |
| NCT00916357 Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | P2 | Completed | 23 | RCT, Double-blind | Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20) |
| NCT01170897 Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 27 | Open-label | PEGPH20 |
| NCT00834704 Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 14 | Open-label | PEGPH20 |
| NCT00803972 Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 | Healthy Volunteers | P1 | Completed | 42 | RCT, Single-blind | rHuPH20, Insulin Human Injection, Insulin Lispro Injection |
| NCT01572012 Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers | Healthy | P1 | Completed | 12 | RCT, Open-label | Ondansetron, Ondansetron + Hylenex, Zofran ODT, Ondansetron solution |
| NCT00493220 Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration | Healthy | P1 | Completed | 30 | RCT, Double-blind | SC HYLENEX and Ceftriaxone, SC Placebo and Ceftriaxone, IV Ceftriaxone |
| NCT03267940 Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | P1 | Terminated | 85 | RCT, Open-label | PEGPH20, CIS, GEM, Atezolizumab |
| NCT00782587 Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer | Superficial Bladder Cancer | P1 | Completed | 14 | Open-label | Chemophase |
| NCT00435604 A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase | Healthy | P1 | Completed | 15 | RCT, Double-blind | Hylenex |
| NCT02563548 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors | NSCLC, Gastric Cancer | P1 | Completed | 56 | Open-label | PEGPH20, Pembrolizumab |
| NCT02667223 Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase | Healthy, Hypercholesterolemia | P1 | Terminated | 60 | RCT, Open-label | Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20, Cohort 5: bococizumab 450 mg + rHuPH20, Cohort 4: bococizumab 300 mg + rHuPH20 |
| NCT00979875 A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone | Healthy | P1 | Completed | 14 | RCT, Double-blind | Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart |
| NCT01275131 Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM) | Type 1 Diabetes Mellitus | P1 | Completed | 45 | RCT, Double-blind | Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20) |
| NCT02346370 A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC | Non-small Cell Lung Cancer | P1 | Terminated | 16 | Open-label | PEGylated recombinant human hyaluronidase PH20, Docetaxel |
| NCT00862849 Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone | Diabetes Mellitus | P1 | Completed | 22 | Double-blind | Insulin Lispro, Regular Human Insulin, rHuPH20 |
| NCT00807963 Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone | Risk Factors for or a Diagnosis of Osteoporosis | P1 | Completed | 31 | RCT, Single-blind | rHuPH20, zoledronic acid |
| NCT00705536 Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 | Diabetes Mellitus | P1 | Completed | 26 | RCT, Double-blind | Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20) |